CML Treatments

PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
NEW YORK, May 28, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:   PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast ...

PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
NEW YORK, May 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast ...

Quality-of-life issues need to be addressed for CML patients, Moffitt researchers say
( H. Lee Moffitt Cancer Center & Research Institute ) Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include depression, fatigue, nausea and change of ...

Singapore research team identifies new drug target in deadly form of leukemia
( Duke University Medical Center ) Researchers at the Duke-NUS Graduate Medical School in Singapore have identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia, giving new hope to future treatments for this deadly form of cancer. 


Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for ...
WHITE PLAINS, N.Y., June 19, 2013 /PRNewswire/ -- This year alone, The Leukemia & Lymphoma Society (LLS) is supporting more than 300 research projects with one goal in mind: Discovering lifesaving therapies ...

Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA ...
NATICK, Mass. -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that data for its lead compound KPT-330 against advanced chronic myeloid leukemia (CML) ...

Bio-Path Holdings Successfully Completes Fifth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal ...
Bio-Path Holdings, Inc. , a biotechnology company developing a liposomal delivery technology for nucleic acid antisense cancer drugs, today announced that it has completed treatment of the fifth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100-1.01 , which is a systemic treatment for blood cancers including acute myeloid leukemia , chronic myelogenous leukemia ...

Capping Drug Prices Scraps The Hippocratic Oath
By Tomas Philipson & George Zanjani

Companion Diagnostics and Other Aspects of Personalized Medicine
NEW YORK, June 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Companion Diagnostics and Other Aspects of Personalized Medicine http://www.reportlinker.com/p01277476/Companion-Diagnostics-and-Other-Aspects-of-Personalized-Medicine.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy ...

Beating blood cancer
Will more leukaemia patients be able to defeat their disease in the years to come?